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Abstract
Purpose The aim of this study was to establish a protocol
for measuring myocardial blood flow (MBF) by PET/CT in
healthy cats. The rationale was its future use in Maine Coon
cats with hypertrophic cardiomyopathy (HCM) as a model
for human HCM.
Methods MBF was measured in nine anaesthetized healthy
cats using a PET/CT scanner and 13NH3 at rest and during
adenosine infusion. Each cat was randomly assigned to
receive vasodilator stress with two or three adenosine
infusions at the following rates (μg/kg per minute): 140
(Ado 1, standard rate for humans), 280 (Ado 2, twice the
human standard rate), 560 (Ado 4), 840 (Ado 6) and 1,120
(Ado 8).
Results The median MBF at rest was 1.26 ml/min per g
(n=9; range 0.88–1.72 ml/min per g). There was no
significant difference at Ado 1 (n=3; median 1.35, range
0.93–1.55 ml/min per g; ns) but MBF was significantly
greater at Ado 2 (n=6; 2.16, range 1.35–2.68 ml/min per g;
p<0.05) and Ado 4 (n=6; 2.11, 1.92–2.45 ml/min per g; p<
0.05). Large ranges of MBF values at Ado 6 (n=4; 2.53,
2.32–5.63 ml/min per g; ns) and Ado 8 (n=3; 2.21, 1.92–
5.70 ml/min per g; ns) were noted. Observed adverse
effects, including hypotension, AV-block and ventricular
premature contractions, were all mild, of short duration and
immediately reversed after cessation of the adenosine
infusion.
Conclusion MBF can be safely measured in cats using
PET. An intravenous adenosine infusion at a rate of
280 μg/kg per minute seems most appropriate to induce
maximal hyperaemic MBF response in healthy cats. Higher
adenosine rates appear less suitable as they are associated
with a large heterogeneity in flow increase and rate pressure
product, most probably due to the large variability in
haemodynamic and heart rate response.
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Introduction
Myocardial blood flow (MBF) can be measured in humans
non-invasively and accurately using PET and 15O-radio-
labelled water or 13N-radiolabelled ammonia at rest and in
response to several stimuli, such as adenosine, bicycle
exercise, dobutamine and the cold pressor test [1–4].
Myocardial perfusion reserve (MPR), the ratio of MBF
during coronary vasodilation to basal MBF, is an integrated
measure of flow through both the large epicardial coronary
arteries and the microcirculation, and has been proposed as
an indirect parameter to evaluate the function of the
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coronary circulation [3, 5]. An abnormal MPR can be due
to narrowing of the epicardial coronary arteries [6] or, in
the absence of angiographically demonstrable atheroscle-
rotic disease, may reflect dysfunction of the coronary
microcirculation [7–11]. In fact, PET is particularly helpful
in circumstances where the MPR is diffusely blunted due
to a widespread abnormality of the coronary microcircula-
tion, such as in hypertrophic cardiomyopathy (HCM) [7,
12, 13].
HCM is the most common cause of sudden cardiac death
in the young as well as a major cause of morbidity and
mortality in the elderly [14]. Interestingly, HCM is also the
most common cardiac disease in domestic cats and
mutations in the feline MYBPC3 have recently been shown
to cause familial HCM [15] in Maine Coon and Ragdoll
cats [16]. Feline familial HCM thus mimics the hereditary
aspects, phenotypic expression, natural history and patho-
logical characteristics of the human familial form of the
disease [17], making these cats an ideal model for studying
the coronary circulation in HCM.
Unfortunately, there is no standardized protocol to assess
MPR in cats and maximal hyperaemic MBF values in cats
are unknown. Only scant data exist on the effects of
adenosine infusion on feline hearts. In isolated perfused cat
hearts adenosine infusion at 2 μg/g heart wet weight per
minute increases left ventricular pressure, heart rate and
coronary conductance (coronary flow/perfusion pressure)
[18]. In pressure-overloaded feline hearts an elevated MBF
has been found with adenosine infusion at a constant rate of
0.543 μg/kg per minute over 7 min using the carbonized
microsphere method [19]. Nevertheless, maximal hyper-
aemic MBF in cats remains unknown.
Thus, the purpose of this study was to establish a
protocol to determine resting and hyperaemic MBF and
MPR by PET in healthy cats for future reference in cats
with HCM. Emphasis was placed on the adenosine dose
necessary to produce maximal MBF and its adverse
effects.
Materials and methods
Animals
Nine healthy cats (six Maine Coon cats from a private
breeder, two laboratory cats and one European domestic
short-hair cat from a private owner) were included in the
study. The two laboratory cats were used at the beginning
of the study for more invasive cardiovascular monitoring.
None of the cats used had a history of cardiac disease
and all were judged to be healthy based on clinical
examination, echocardiography and blood examination.
Their weight range was 3.7–10.5 kg (median 4.7 kg), their
age range was 7–75 months (median 16 months), and there
were six male and three female cats. All examinations were
performed with written permission of the Federal Veteri-
nary Office, Secretariat of Animal Research, Zurich,
Switzerland.
Anaesthesia
The cats were sedated with intramuscular buprenorphine
(Temgesic; Essex Chemie, Luzern, Switzerland) 0.003 mg/kg
and acepromazine (Prequillan; Arovet, Zollikon-Station,
Switzerland) 0.01 mg/kg. Anaesthesia was induced 20 min
later with propofol (Propofol 1%; Fresenius, Stans, Switzer-
land) 2–5 mg/kg intravenously (i.v.) and sustained with
isoflurane and oxygen inhalation.
Monitoring
In all cats heart rate, respiratory rate, oxygen saturation, and
electrocardiogram (ECG) were continuously monitored.
Additionally, in two laboratory cats direct arterial blood
pressure (BP) was continuously measured with a catheter in
the right femoral artery, and in two other cats indirect
arterial BP was noninvasively measured at the right femoral
artery. All measurements were done with a Cardiocap/5
system (Datex-Ohmeda Division, Finland).
PET
PET studies were performed using a whole-body scanner
(Discovery LS PET/CT scanner; GE Healthcare, Milwau-
kee, WI), which is an integration of an Advance NXi PET
scanner, which records 35 image planes simultaneously,
with a LightSpeed plus multislice helical CT scanner. The
axial field of view was 14.5 cm. Correct positioning of the
cat’s heart within the axial field of view of the tomograph
was confirmed on a rectilinear transmission scan (Fig. 1).
This CT scan was also used for photon attenuation
correction as previously described [20]. All scans were
performed using 13N-labelled ammonia (350–400 MBq).
Starting with the i.v. administration of the tracer into the
cephalic vein, nine frames of 10 s, six frames of 15 s, two
frames of 30 s, one frame of 60 s, and one frame of 900 s
were recorded [13].
MBF was measured at rest followed by serial measure-
ments during adenosine-induced hyperaemia at intervals of
50 min to allow for decay of 13N.
Study protocol
Adenosine was administered as a continuous rate infusion,
which was started 3 min before injection of the tracer and
continued for 4 min more. In the pilot study (one cat) the
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adenosine dose chosen for hyperaemic MBF measurement
was the human standard rate of 140 μg/kg per minute
(Ado 1). The remaining cats received two (n=3) or three
(n=5) different adenosine doses. The adenosine doses
chosen were the human standard dose (Ado 1, n=3), twice
the human standard dose (Ado 2, 280 μg/kg per minute, n=
6), four times the human standard dose (Ado 4, 560 μg/kg
per minute, n=6), six times the human standard dose
(Ado 6, 840 μg/kg per minute, n=4), and eight times the
human standard dose (Ado 8, 1,120 μg/kg per minute, n=
3). The doses and their sequence of administration in
individual cats were randomly assigned.
Estimates of myocardial blood flow
Transaxially acquired images were reoriented to obtain
short axis images of the heart. A basal, a midventricular,
and an apical slice were then chosen for further analysis. In
each slice a region of interest (ROI) was placed within the
septal, anterior, lateral, and inferior segments. A spherical
ROI was placed in the blood pool of the left ventricle
(Fig. 1). Myocardial and blood pool time–activity curves
were generated from the dynamic frames and corrected for
radioisotope decay. MBF was estimated by model fitting of
the blood pool and myocardial time–activity curves [21].
Partial volume and spillover (both accounting for the
resolution distortion) were corrected as previously reported
[11, 13, 22] using the method developed [23] and validated
[24] by Hutchins et al. MPR was calculated as the ratio of
hyperaemic to resting MBF values [10, 13, 22]. Under
normal conditions, myocardial oxygen consumption is
linearly related to the heart rate–BP product (RPP), an
index of external cardiac work, and both are related to
coronary blood flow [9]. To allow meaningful interpretation
of the quantitative data, it has been proposed that resting
MBF be corrected for RPP. In view of the median RPP
value of 15,000 under anaesthesia at rest in the present
study, it seemed appropriate to use this value for normali-
zation. In addition, to account for the variability of coronary
driving pressure, coronary resistance (mmHg×min×g×ml−1)
was also calculated as the ratio of mean arterial pressure
(MAP) to MBF [9].
Statistical analysis
Values are given as medians and range, as no normal
distribution could be assumed due to lack of previous
empirical data. Differences in hyperaemic MBF at various
adenosine doses as well as correlations between adenosine
dose and MBF were calculated using nonparametric
methods and a commercial statistical software solution
(SPSS, Statistical Package for the Social Sciences, software
for Windows, version 11). P values <0.05 were considered
statistically significant.
Results
Haemodynamics and physiological data
Heart rate was constant (median 155, range 113–188 beats/
min) throughout 17 of 22 PET scans with adenosine. In five
scans, heart rate markedly increased (by a median of 30,
range 20–80 beats/min) during adenosine infusion (Table 1).
MAP decreased from 89 mmHg at baseline to 56 mmHg
and to 61 mmHg during adenosine infusion at Ado 2 and
Ado 6, respectively, and returned to baseline within 1 min
after the end of the infusion in one cat with invasive BP
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Fig. 1 a CT transmission scan of intubated cat. b ROIs on the left and right ventricular cavities and myocardial tissue drawn on a short axis slice
of the heart. c Time–activity curves of left ventricular (LV) blood pool (input function), right ventricular (RV) blood pool, and LV myocardium
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measurement. In this cat during adenosine infusion at
Ado 2, heart rate increased from 136 to 159 beats/min,
and during infusion at Ado 6 heart rate increased from 136
to 186 beats/min. In the second cat with invasive BP
monitoring there was no relevant decrease in MAP with
adenosine infusion at Ado 4 or Ado 8. With infusion at
Ado 8, this cat seemed to be waking up from anaesthesia
showing palpebral reflex activity associated with a rise in
heart rate from 159 to 172 beats/min, which returned to
baseline after stopping the adenosine infusion.
In one cat with indirect BP measurement calculated
MAP decreased from 75 mmHg at baseline to 41, 50 and
60 mmHg with adenosine infusion at Ado 8, Ado 6 and
Ado 2, respectively, returning to baseline within 1–3 min at
the end of the infusions. With the highest adenosine dose,
heart rate increased from 138 to 172 beats/min. In the other
cat with noninvasive monitoring there was no relevant
MAP decrease or heart rate increase with infusion at Ado 6,
Ado 4 or Ado 2.
ECG abnormalities occurred in three cats, all during
adenosine infusion at Ado 4, consisting of singular
monofocal ventricular premature contractions (VPCs), a
single short episode of second degree 3:1 AV-block, and an
episodic second degree AV-block. Subsequently, at higher
doses of adenosine (Ado 6 and Ado 8) no ECG abnormal-
ities were detected in any of the cats. Respiratory rate at
17–21 breaths per minute and oxygen saturation above 94%
remained stable throughout the study in all scans.
Myocardial blood flow and perfusion reserve
Median MBF was 1.26 ml/min per g (n=9; range 0.88–
1.72 ml/min per g) with minimal change after correction for
RPP (median 1.59, range 1.16–1.72 ml/min per g)
indicating comparable haemodynamic conditions. There
was no significant change at Ado 1 (n=3; median 1.35,
range 0.93–1.55 ml/min per g; ns) but a significant increase
at Ado 2 (n=6; median 2.16, range 1.35–2.68 ml/min per g;
p<0.05) and Ado 4 (n=6; median 2.11, range 1.92–
2.45 ml/min per g; p<0.05). A large range of MBF
response was noted at Ado 6 (n=4; median 2.53, range
2.32–5.63 ml/min per g; ns) and Ado 8 (n=3; median 2.21,
range 1.92–5.70 ml/min per g; ns). Interestingly, at the
highest rates, the MBF response was declining again in
some cats (Fig. 2).
Median MPR was 1.42 (range 1.05–1.74) at Ado 1, 1.65
(range 1.22–2.30) at Ado 2, 1.54 (range 1.50–2.19) at
Ado 4, 1.92 (range 1.35–6.39) at Ado 6, and 1.90 (range
1.20–4.13) at Ado 8. Consequently, the coronary resistance
decreased from 66 mmHg×min×g×ml−1 at rest to 60, 33,
31, 24 and 36 mmHg×min×g×ml−1 at Ado 1, Ado 2,
Ado 4, Ado 6 and Ado 8, respectively.
Discussion
Our study showed that MBF can be measured in cats by
PET with 13NH3 as flow tracer. MBF can be manipulated in
cats by adenosine infusion. A primary goal of this study
was to establish the ideal adenosine dose for obtaining the
MPR in cats. The ideal dose would consistently result in
Fig. 2 Myocardial blood flow (median and range) in healthy cats
measured at rest (Ado 0) and after stimulation by increasing dosages
of adenosine infused over 7 minutes (Ado 2–Ado 8). The adenosine
dosage is given in relation to the human standard dose (Ado 1)
140 μg/kg/min; Ado 2=twice human standard dose, 280 μg/kg/min;
Ado 4=560 μg/kg/min, Ado 8=1120 μg/kg/min
Table 1 Haemodynamics
At rest Ado 1 Ado 2 Ado 4 Ado 6 Ado 8
Blood pressure (mmHg)
Systolic 109 128 109 96 88 99
Diastolic 58 58 44 42 42 60
Mean 83 81 72 66 63 79
Heart rate (beats/min) 142 161 155 147 157 162
Rate–pressure product 15,478 20,608 16,895 14,112 13,816 16,038
In normal anaesthetized cats maintained with isoflurane inhalation, heart rate is 184±28 beats/min and blood pressure values are systolic 110±
19 mmHg, diastolic 72±17 mmHg and mean 85±17 mmHg, resulting in a calculated RPP of 20,240 [29].
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maximal MBF without causing relevant adverse effects. In
our cats MBF first increased with increasing adenosine
dose, but at high doses again decreased in some animals. At
adenosine rates of 280 (Ado 2) and 560 μg/kg per minute
(Ado 4) similar results were obtained, and the increase in
MBF was most consistent. At Ado 2 haemodynamic
parameters including RPP were unchanged compared to
values at rest, thus excluding confounding effects by
changes in cardiac work.
There were no serious adverse effects to adenosine
noted, even at higher doses. The few side effects including
hypotension, AV block, VPCs and waking up from
anaesthesia were all mild, of short duration, and immedi-
ately reversed at the end of the adenosine infusion. With the
exception of waking up from anaesthesia which only
occurred at high adenosine doses, the incidence of side
effects was not related to the adenosine dose; in several
instances cats did exhibit adverse effects at a lower dose,
but not at a higher dose. Based on all these findings and
considerations, adenosine administration at a rate of
280 μg/kg per minute over 6–7 min is suggested for use
as the standard dose for the determination of maximal MBF
and to calculate MPR in anaesthetized cats. While this
corresponds to twice the standard microgram per kilogram
dose used in human studies, it matches the human standard
dose when calculated in relation to body surface area in
micrograms per metre squared. Studies in cats with HCM
will have to show whether this adenosine dose is equally
well tolerated in these cats, and whether differences in MBF
and MPF can be observed and assessed by PET as
compared to healthy cats.
At rest, higher values of MBF were obtained in our
anaesthetized cats than in awake humans. With a few
exceptions the hyperaemic MBF response was in the range
of 1.5–5.0 ml/min per g in our healthy anaesthetized cats,
which is comparable to the values reported in awake
humans [1, 25, 26] and anaesthetized rats [27, 28].
However, the resulting MPR values ranging between 1.5
and 2.5 were markedly lower than values obtained in awake
healthy humans in whom MPR values in the range 2.5–4.0
are generally considered normal. The lower MPR in our
anaesthetized cats can mostly be explained by their higher
resting MBF. Nevertheless, our results compare well with
MPR values reported in anaesthetized rats, in which MPR
values range between 1.5 and 2.5 [27]. In two cats we
obtained substantially higher MPR values, i.e. 6.4 at Ado 6
and 4.1 at Ado 8. The latter was the cat which woke up
repeatedly during infusion of that dose. In the former, heart
rate increased markedly from 120 to 189 beats/min,
suggesting that this cat also was waking up from anaesthe-
sia. This was reflected by a slight increase in minimal
coronary resistance during adenosine infusion at the
maximal dose. Thus, the much lower MPR in our study
as compared to values found in humans may, at least in
part, be attributed to effects of the anaesthesia. Likewise,
anaesthesia has been shown to affect MBF in rats [27]. As
ethical and feasibility issues demand anaesthesia for
measuring MBF by PET in animals but is not ethically
justifiable nor technically needed in humans, direct com-
parison of measurements between animal and human
studies are precluded. A further limitation has to be
acknowledged with regard to the technical equipment. The
scanner used was suited to clinical use and the transaxial
resolution was around 6 mm; the left ventricular wall of the
cat may reach 5.5–6 mm with a heart rate twice that in
humans. In order to allow for these limitations we used
partial volume and spillover correction as mentioned above.
We did not perform simultaneous measurements of MBF
with another method such as radiolabelled or stable
isotopically labelled microspheres to confirm the PET
measurements.
Conclusion
MBF can be measured by PET in anaesthetized cats using
13NH3 and our results suggest the use of adenosine at a rate
of 280 μg/kg per minute over 6–7 min. Future studies will
have to determine the value of measuring MBF by PET for
identifying abnormal coronary perfusion in cats with HCM,
for identifying different degrees of HCM in cats, and
potentially for identifying early and subclinically affected
animals without echocardiographically detectable morpho-
logical abnormalities.
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